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Key points 26 
Question: Is the beneficial effect of liraglutide on the risk of first major 27 
adverse cardiovascular events (MACE) maintained when subsequent 28 
events are also included?  29 
Findings: In LEADER, a total of 1605 MACE occurred, comprised of 1302 30 
first and 303 recurrent events. Liraglutide was associated with a 16% 31 
relative risk reduction for total MACE versus placebo. 32 
Meaning: Considering the overall burden of cardiovascular events, these 33 
data reaffirm the efficacy of liraglutide in patients with type 2 diabetes 34 




Structured abstract 36 
Importance: Following non-fatal cardiovascular events, recurrent events 37 
are highly likely. Most cardiovascular outcomes trials analyze first events 38 
only, but extending analyses to first and recurrent (total) events can 39 
provide clinically meaningful information. 40 
Objective: To investigate our hypothesis, formulated after data collection 41 
for the LEADER trial, that liraglutide would reduce both first and recurrent 42 
major adverse cardiovascular events (MACE) compared with placebo in 43 
patients with type 2 diabetes at high cardiovascular risk. 44 
Design: The LEADER trial was a randomized, double-blind, placebo-45 
controlled cardiovascular outcomes trial; this post hoc analysis used 46 
expanded Cox regression models. 47 
Setting: LEADER was a global, multi-center trial. 48 
Participants: LEADER included patients with type 2 diabetes and with 49 
established or high risk for cardiovascular disease. 50 
Interventions: Patients received liraglutide (up to 1.8 mg/day) or 51 
placebo (randomization ratio 1:1), both with standard care, for 3.5–5 52 
years. 53 
Main outcomes and measures: Assessed outcomes were MACE 54 
(cardiovascular death, non-fatal myocardial infarction and non-fatal 55 




and hospitalization for heart failure or unstable angina pectoris [UAP]), 57 
and the individual endpoints. 58 
Results: The 9340 LEADER participants experienced 1605 total MACE 59 
(1302 first and 303 recurrent events, median follow-up = 3.8 years). 60 
Patients who experienced any MACE tended to be older and have diabetes 61 
for longer than patients without MACE. In the liraglutide group, fewer first 62 
and recurrent MACE (608/4668 and 127/4668 events/patients, 63 
respectively) versus placebo (694/4672 and 176/4672 events/patients) 64 
occurred. Liraglutide, therefore, was associated with a 16% relative risk 65 
reduction for total MACE versus placebo (hazard ratio [HR] 0.84, 95% 66 
confidence interval [CI] 0.76–0.93) and a 13% reduction for total 67 
expanded MACE versus placebo (HR 0.87, 95% CI 0.81–0.93). When 68 
individual endpoints were considered (with the exception of UAP), 69 
liraglutide was associated with lower risk versus placebo. 70 
Conclusion and relevance: Taken together, these data extend the 71 
primary analysis and show that liraglutide reduces recurrent events 72 
versus placebo in patients with type 2 diabetes at high cardiovascular 73 
risk. This analysis strengthens the absolute benefit of liraglutide with 74 
respect to the overall burden of cardiovascular events in this high-risk 75 
patient population. 76 






Several recent cardiovascular outcomes trials (CVOTs) with 80 
antihyperglycemic therapies demonstrate significant cardiovascular (CV) 81 
benefits for patients with type 2 diabetes at high CV risk, including: 82 
EMPA-REG,1 LEADER,2-4 SUSTAIN 6,5 CANVAS,6 and HARMONY 83 
Outcomes.7  84 
LEADER was a randomized, double-blind, placebo-controlled CVOT of 85 
liraglutide (maximum 1.8 mg/day) versus placebo, both added to 86 
standard care for 3.5–5 years in patients with type 2 diabetes and high 87 
risk for CV disease.2 The primary analysis demonstrated superiority of 88 
liraglutide over placebo for major adverse CV events (MACE) – a 89 
composite endpoint of CV death, non-fatal myocardial infarction (MI), or 90 
non-fatal stroke (hazard ratio [HR] 0.87, 95% confidence interval [CI] 91 
0.78–0.97; p=0.01 for superiority).2  92 
The majority of CVOTs on diabetes have used time to first MACE as the 93 
primary endpoint.1,2,5,6 However, following an initial non-fatal event, there 94 
is a high likelihood of a recurrent CV event.8 A total events analysis, 95 
capturing both first and recurrent events, can provide important 96 
information that may help to guide clinical decision-making from the 97 
perspectives of both patient risk and economics. 98 
In this novel, multiple Cox-regression model analysis from the LEADER 99 
trial, we sought to evaluate the efficacy of the glucagon-like peptide-1 100 




any MACE, as well as on expanded MACE (included coronary 102 
revascularization and hospitalization for heart failure or unstable angina 103 
pectoris [UAP], in addition to primary MACE). 104 
 105 
Methods 106 
We hypothesized that liraglutide would reduce total (both first and 107 
recurrent) MACE, when compared with placebo. In this post hoc analysis 108 
we used expanded Cox regression models (described below) to estimate 109 
the effect of liraglutide on risk of total MACE, total expanded MACE (MACE 110 
endpoints, coronary revascularization, or hospitalization for heart failure 111 
or UAP), and the individual CV endpoints in the LEADER trial. The full 112 
LEADER methodology (including its ethical approval and written informed 113 
consent details) has been reported previously.2,9 Events were adjudicated 114 
by an external events adjudication committee (EAC), who determined if 115 
multiple events within one patient constituted separate events or were all 116 
related to the same event.2,9 117 
Andersen-Gill proportional intensity (AG) model for recurrent events  118 
The AG model originates from the well-known Cox regression model 119 
(proportional hazard model) and assumes that the baseline intensity is 120 
the same across time, independent of the number of events.10,11 Hence, 121 
there is no inherited assumption in the model that an event will decrease 122 
or increase the likelihood of the next event. EAC-adjudicated separate 123 




which is considered to be a strong assumption. In the AG model, it is 125 
suggested to incorporate usually time-dependent variables that could 126 
mitigate the assumption of independence; for example, this could be the 127 
number of previous events (or functions thereof) for each patient at the 128 
time of a recurrent event.10,11 We used two AG models. The unadjusted 129 
AG model included randomized treatment only, whereas the adjusted AG 130 
model included previous events as a time-dependent continuous variable 131 
and randomized treatment as a fixed factor. Furthermore, in both AG 132 
models, we used the robust (sandwich) estimator of the variance with 133 
patient as the cluster to account for dependence between events within 134 
patients.12  135 
Prentice-Williams-Peterson (PWP) survival model for recurrent events 136 
The PWP model is different from the AG model as the baseline intensity is 137 
allowed to vary depending on the number of events, as the model is 138 
stratified on this group.10,11 Hence, the baseline hazard is allowed to be 139 
different within the number of events. All patients are at risk for a first 140 
event, but a patient could only be at risk for a recurrent event after the 141 
first event has occurred. The PWP model can incorporate both common 142 
and event-specific effects for each covariate; therefore, unlike the AG 143 
model, the effect of covariates may vary from event to event in the PWP 144 
model, i.e. the effect of randomized treatment can differ according to 145 
event order.10,11 We used the PWP-total-time model for results pertaining 146 




model used the same data structure as the AG model, but with a 148 
supplementary stratum variable defined by the number of events within 149 
each patient.  150 
Other than the adjustments detailed above, no other adjustments were 151 
made for baseline characteristics in these analyses. 152 
Mean cumulative function (MCF) and number needed to treat (NNT) 153 
The MCF was estimated using the Nelson–Aalen non-parametric method. 154 
The NNT for event prevention was based on the difference between the 155 
MCF for each treatment arm at 3 years.13 A sensitivity analysis was 156 
performed to account for non-CV death as competing risk, which was 157 
estimated with the mean cumulative function, as per previously published 158 
methods.14,15 159 
 160 
Results  161 
 162 
Baseline characteristics and distribution of MACE, expanded MACE and 163 
individual CV endpoints 164 
A total of 1605 MACE occurred during LEADER, of which 1302 were first 165 
events and 303 were recurrent events (Figure 1). Patients who 166 
experienced any MACE tended to be older, with a longer duration of 167 
diabetes, higher hemoglobin A1C levels and more frequent prior MI and/or 168 
heart failure at baseline than those who did not experience MACE (Table 169 




those who experienced recurrent MACE, compared with the ‘no MACE’ and 171 
‘single MACE’ groups (Table 1). There was a median follow-up time of 3.8 172 
years,2 allowing robust analyses of data at 3 years. 173 
There were 135 fewer total MACE with liraglutide than placebo (Figure 174 
1a). This translated to an NNT of 43 patients to prevent one such event 175 
at 3 years (Figure 2) and an NNT of 37 patients when accounting for 176 
non-CV death as competing risk. The mean cumulative functions taking 177 
into account non-CV death tended to be slightly lower for both treatment 178 
groups, but slightly more marked for the liraglutide group (Figure 2). 179 
Recurrent MACE occurred in 97 patients (2.1%) on liraglutide and in 126 180 
(2.7%) on placebo, seemingly driven by reductions in the proportions of 181 
patients experiencing recurrent non-fatal MI and stroke. Likewise, fewer 182 
patients experienced recurrent expanded MACE with liraglutide (n=416, 183 
8.9%) versus placebo (n=471, 10.1%), with correspondingly fewer total 184 
events (Figure 1b). For expanded MACE, the NNT was estimated to be 185 
23 patients at 3 years (Figure 2), and 21 patients, when non-CV death 186 
was included as a competing risk. Overall, few patients experienced 187 
recurrent events of individual CV endpoints, and (with the exception of 188 
UAP) consistently lower numbers of recurrent events occurred with 189 





Risk of total MACE, total expanded MACE and individual CV endpoints 192 
The unadjusted AG model with a robust variance estimation showed that 193 
liraglutide was associated with a 16% relative risk reduction for total 194 
MACE versus placebo: HR 0.84 (95% CI 0.76–0.93). For the adjusted AG 195 
(HR 0.86 [95% CI 0.78–0.95]) and PWP model (HR 0.87 [95% CI 0.78–196 
0.95]), risk estimates were slightly higher. In addition, liraglutide was 197 
associated with a 13% relative risk reduction for total expanded MACE 198 
versus placebo (unadjusted AG model: HR 0.87 [95% CI 0.81–0.93]), 199 
and when all individual CV endpoints were considered (with the exception 200 
of UAP), liraglutide was associated with lower risk versus placebo (eTable 201 
1). 202 
The post hoc inclusion of recurrent events increased the power for 203 
showing superiority for time to EAC-confirmed MACE from 72% (primary 204 
endpoint of first MACE, Cox regression]) to 82% (post hoc endpoint of 205 




We hypothesized that liraglutide, in addition to reducing first MACE in 210 
patients with type 2 diabetes at high CV risk, would also reduce recurrent 211 
CV events, and therefore total events, when compared with placebo. As 212 
we have shown previously, liraglutide reduced the relative risk of first 213 




the relative risk reduction for total MACE was 16%. For total MACE, this 215 
translated into 43 patients needing treatment with liraglutide to prevent 216 
one event over 3 years, which is considerably lower than the NNT of 66 217 
calculated based on first MACE alone.2 Similarly, for expanded total MACE 218 
the NNT was 23 versus 49 for expanded first MACE. These are the first 219 
such data relating to liraglutide and should help to guide clinical decisions, 220 
as the use of liraglutide reduces both first and recurrent MACE in patients 221 
at risk of CV disease. 222 
Although it is commonplace in CVOTs to censor primary outcome data 223 
after the first event has occurred,1,2,5-7 many individuals have additional 224 
CV events, which are captured and adjudicated, but not used in primary 225 
statistical efficacy analyses. The clinical and scientific utility of capturing 226 
the total events may increase the power of the study, assuming efficacy is 227 
maintained against recurrent events and patients adhere to treatment. It 228 
may also allow for a more meaningful assessment of absolute risk 229 
reduction/NNT with the pharmacotherapy. Indeed, this concept is gaining 230 
support in other CV risk-reduction trials, including those of lipid-lowering16 231 
and antiplatelet therapy,17 as well as cost-effectiveness assessments.18,19 232 
As with the majority of clinical trials, study treatment (liraglutide or 233 
placebo) began at the start of LEADER. However, with the 234 
cardioprotective benefit of liraglutide evident in first MACE and total 235 
MACE, the question arises as to how the timing and duration of liraglutide 236 




question of clinical importance that has yet to be tested in a randomized 238 
clinical trial setting. 239 
Recurrent event analyses have been conducted for different treatments 240 
and diseases, and the proportion of recurrent events reported here was 241 
within the range of those reported in other trials (18–37%).16,17,20 In an 242 
analysis of ischemic events (CV death, non-fatal MI, non-fatal stroke, 243 
coronary revascularization, or hospitalization for unstable angina) in 244 
patients with established CV disease or type 1 or 2 diabetes and treated 245 
with statins, icosapent ethyl (an anti-lipid therapy) reduced the relative 246 
risk of total events by 30% versus placebo over 4.9 years.20 These 247 
previously published data show that recurrent events occur in a 248 
substantial proportion of patients and need to be considered when making 249 
clinical decisions.   250 
This analysis has limitations. Analyses of recurrent events may 251 
overestimate the contribution of patients experiencing MACE early in a 252 
trial,8 cannot differentiate between cardioprotective mechanisms of a drug 253 
that may differ between first and subsequent events,16 and do not 254 
account for the decreasing compliance, which is nominally reported as 255 
CVOTs progress.16 While the mean percentage of time on treatment for 256 
patients in the liraglutide group was 84% and in the placebo group was 257 
83%,2 it was uncertain as to the adherence to study drug in the period 258 
between first and recurrent MACE. This lack of data is a potential 259 




completing a final study visit, who died or had a primary outcome,2 261 
demonstrating the overall robustness of the data. There was also a lack of 262 
data about CV medication use between first and recurrent MACE, which 263 
potentially biased the results. Also, although inclusion of recurrent events 264 
increased the post hoc power, LEADER was not designed to test for 265 
treatment differences in recurrent events. Although such analyses of 266 
recurrent events may amplify any positive result for primary events (as 267 
counting each recurrent event individually may augment the effect size), 268 
in CVOTs this has to be considered in parallel with any differences in CV 269 
versus non-CV death. In the analyses of recurrent events for the 270 
composite endpoint MACE and expanded MACE, non-CV death was a 271 
competing event. As only a marginal non-significant treatment difference 272 
was observed for non-CV death in LEADER (HR 0.95, 95% CI 0.76–273 
1.18),2 it was likely that this competing risk would only have a marginal 274 
impact on the results. This was supported by the sensitivity analyses of 275 
the mean cumulative function for both endpoints. For the analyses of the 276 
individual components, CV death and non-CV death were competing 277 
events. A treatment effect in favor of liraglutide was observed for all-278 
cause death in LEADER with a HR of 0.85 (95% CI 0.74–0.92).2 Hence, 279 
the results for the recurrent models applied for the individual components 280 
in (expanded) MACE could potentially be biased towards neutrality of the 281 
treatment effects. 282 
A final potential limitation was related to the statistical approaches used. 283 




its use of the event history may reduce the estimated treatment effect10 285 
and, furthermore, there could be a selection bias as randomization is not 286 
preserved after the first event. However, in a recent paper by Ozga and 287 
colleagues,11 the PWP model seemed to be advantageous (followed by the 288 
AG model) in estimating treatment effects. It met most data scenarios for 289 
clinical trials with composite endpoints including fatal events, as 290 
compared with marginal recurrent models such as the Wei-Lin-Weissfeld 291 
model.11  292 
Altogether, these data extend the primary analysis, and reaffirm the 293 
efficacy of liraglutide in reducing recurrent MACE in patients with type 2 294 
diabetes at high CV risk. This strengthens the absolute benefit of 295 
liraglutide with respect to the overall burden of CV events in this high-risk 296 
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Figure legends 427 
Figure 1. Number of total (first and recurrent) CV events during 428 
the LEADER trial 429 
 430 
A) Number of MACE, B) Number of expanded MACE and C) Number of individual 431 
CV endpoints. 432 
Total number of patients in the liraglutide group = 4668. Total number of 433 
patients in the placebo group = 4672. a3-point composite endpoint: time to CV 434 
death, non-fatal MI, or non-fatal stroke. b6-point composite endpoint: included 435 
MACE endpoints, plus coronary revascularization and hospitalization for heart 436 
failure or UAP. HRs (95% CI) for recurrent events were calculated using the 437 
pooled treatment effects across event numbers ≥2 from the PWP model. 438 
CI, confidence interval; CV, cardiovascular; HR, hazard ratio; MACE, major 439 
adverse cardiovascular events; MI, myocardial infarction; n, total number of 440 
events; PWP, Prentice–Williams–Peterson; UAP, unstable angina pectoris. 441 
 442 
 443 
Figure 2. Mean total MACE per patient over the trial period 444 
 445 
a3-point composite endpoint: time to CV death, non-fatal MI, or non-fatal stroke. 446 
b6-point composite endpoint: included MACE endpoints, plus coronary 447 




MCF estimated using the Nelson-Aalen non-parametric method; NNT based on 449 
the MCF at 3 years without taking into account competing risk.  450 
CV, cardiovascular; MACE, major adverse cardiovascular events; MI, myocardial 451 
infarction; MCF, mean cumulative function; NNT, number needed to treat to 452 




Table 1. Baseline characteristics of patients in LEADER by number of MACE experienced 454 
Number of MACE 
experienced 
No MACE A single MACE >1 MACE 
Treatment group 
Liraglutide  Placebo  Liraglutide  Placebo  Liraglutide  Placebo  
(n=4060) (n=3978) (n=511) (n=568) (n=97) (n=126) 
Age, years 64.0 (7.2) 64.1 (7.0) 65.5 (7.7)  65.8 (8.2) 65.0 (7.4) 66.2 (8.3) 
Male, n (%) 2586 (63.7) 2507 (63.0) 361 (70.6) 402 (70.8) 64 (66.0)  83 (65.9) 
Diabetes duration, years 12.7 (7.9) 12.7 (8.0) 13.3 (8.1) 13.4 (8.5) 15.1 (8.7) 13.8 (8.7) 
Hemoglobin A1C, % 8.7 (1.5) 8.6 (1.5) 8.9 (1.7)  8.8 (1.6) 9.0 (1.7)  9.0 (1.7) 
Prior MI, n (%) 1182 (29.1)  1077 (27.1) 202 (39.5) 245 (43.1) 50 (51.5) 51 (40.5) 
Prior HFa, n (%) 541 (13.3) 533 (13.4) 94 (18.4) 99 (17.4)  18 (18.6) 20 (15.9) 
Body weight, kg 91.7 (21.1)  91.4 (20.7) 93.1 (22.0) 92.6 (21.5) 93.0 (20.1)  92.2 (20.6) 
BMI, kg/m2 32.6 (6.3)  32.5 (6.3) 32.3 (6.4)  32.4 (6.4)  32.9 (6.5) 32.8 (6.2) 
       
Data are mean (SD) unless otherwise stated. MACE: 3-point composite endpoint of time to CV death, non-fatal MI, or non-455 
fatal stroke. aPrior chronic HF (New York Heart Association class II or III). BMI, body mass index; CV, cardiovascular; 456 
hemoglobin A1C, glycated hemoglobin; HF, heart failure; MACE, major adverse cardiovascular events; MI, myocardial 457 
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NNT at 3 years
MACEa: 43 patients
Expanded MACEb: 23 patients
3 4
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Placebo
